Among these avenues, inhibitors of amyloid precursor protein (APP) protease, β-site cleaving enzyme 1 (BACE1), and cyclin-dependent kinase 5 (CDK5) contributing to tau phosphorylation have been suggested as appealing drug targets for AD [9,10,11,12]. The gene discussed is BACE1; the disease is Alzheimer disease.